PA
CLF icon

PharVision Advisers’s Cleveland-Cliffs CLF Stock Holding History

PharVision Advisers’s Portfolio CLF Stock Details CLF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$124K Buy
13,160
+2,387
+22% +$26.2K 2.33% 5
2026
Q1 		$91K Sell
10,773
-4,454
-29% -$51K 0.92% 57
2025
Q4 		$202K Buy
+15,227
New +$192K 0.1% 550

Other funds holding CLF

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $2.64B AUM 24.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PharVision Advisers's CLF Position: Q2 2026 in Review

PharVision Advisers increased its Cleveland-Cliffs (CLF) stake by 22% in Q2 2026, buying an estimated $26.2K and bringing the position to 13,160 shares worth $124K. The position accounts for 2.33% of the portfolio, ranked #5.

PharVision Advisers first reported a position in CLF in Q4 2025 and has held it in 3 quarters since. The position peaked at $202K in Q4 2025. 584 funds tracked by Wall St. Rank hold CLF as of Q2 2026.

  • PharVision Advisers held 13,160 shares of Cleveland-Cliffs worth $124K as of Q2 2026.
  • PharVision Advisers bought 2,387 Cleveland-Cliffs shares in Q2 2026, an estimated $26.2K.
  • Cleveland-Cliffs made up 2.33% of PharVision Advisers's portfolio in Q2 2026, its #5 holding.
  • PharVision Advisers first reported a position in Cleveland-Cliffs in Q4 2025 and has held it in 3 quarters since.
  • PharVision Advisers's Cleveland-Cliffs position peaked at $202K in Q4 2025.
  • 584 funds tracked by Wall St. Rank held Cleveland-Cliffs as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.